AML Findings Suggest a Broader Role for Genomic Testing

Brittany Lovely
Published: Thursday, Aug 15, 2019
Christopher Hourigan, MD, DPhil

Christopher Hourigan, MD, DPhil

Genomic profiling provides evidence of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation (alloHCT), according to findings presented at the 2019 European Hematology Association Congress.

Table. Custom Gene Panel for Detection of MRD in AML1

Table. Custom Gene Panel for Detection of MRD in AML1 In their supplementary study, Hourigan and colleagues evaluated 188 whole blood samples from participants in the BMT CTN trial, collected equally from patients who received RIC and MAC who were well matched for other baseline characteristics.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x